SCHEMBL2479313

SCHEMBL2479313

Cc1cccnc1[C@H]1CCC[C@@H](c2ncccc2C)N1CCCC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 5/20 0.40
CNR2 P34972 2/20 0.40
PDE10A Q9Y233 1/20 0.38
FFAR4 Q5NUL3 5/20 0.37
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15387150 0.96 CNR2 (0.41) CXCR4CNR2PDE10AFFAR4FNTA
SCHEMBL2476483 0.90 CXCR4 (0.40) CXCR4PDE10AOPRL1TRPV1ATM
SCHEMBL2476650 0.87 HDAC6 (0.41) CXCR4ATM
SCHEMBL2474572 0.86 CNR2 (0.44) CXCR4CNR2
SCHEMBL2475030 0.86 HCRTR1 (0.39) CXCR4OPRL1TRPV1ATM
SCHEMBL26523222 0.85 CXCR4 (0.43) CXCR4CNR2OPRL1
SCHEMBL30586952 0.85 CXCR4 (0.43) CXCR4CNR2OPRL1
SCHEMBL26107971 0.85 CXCR4 (0.43) CXCR4CNR2OPRL1
SCHEMBL2470568 0.84 HDAC3 (0.44)
SCHEMBL2476439 0.84 CXCR4 (0.44) CXCR4CNR2OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615633-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY GENZYME CORP (US) 2012-08-15 EP disclosed
EP-2374804-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy Genzyme Corporation (US) 2011-10-12 EP disclosed
US-7550484-B2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy GENZYME CORPORATION (US) 2009-06-23 US disclosed
US-20050059702-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED CORPORATION (CA) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059702-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy CXCR4, CXCR1, CCR5 CXCR4 1/4885CNR2 146/4885PDE10A 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.